Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Publication Date: November 29, 2018
Last Updated: December 15, 2022
Treatment
Updated Recommendations on Extended Therapy
Many women with node-negative breast cancer are potential candidates for and may be offered extended AI therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors. However, as the recurrence risk is lower, the benefits are likely narrower for such patients. Women with low-risk node-negative tumors should not routinely be offered extended therapy. (, , )
6539
Title
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Authoring Organization
American Society of Clinical Oncology